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Abstract
Introduction: Autopsy series have shown that metastasis to the thyroid gland has occurred in up to 24% of
patients who have died of cancer. Neuroendocrine tumors may metastasize to thyroid gland.
Case presentations: Case 1 was a 17-year-old Turkish woman who was referred from our Endocrinology
Department for a thyroidectomy for treatment of neuroendocrine tumor metastasis. She was treated with a
bilateral total thyroidectomy. Histopathological examination results were consistent with a neuroendocrine tumor;
neoplastic cells showed strong immunoreactivity to chromogranin A and synaptophysin, but the
immunohistochemical profile was inconsistent with medullary thyroid carcinoma in that the tumor was negative
for calcitonin, carcinoembryonic antigen, and thyroid transcription factor-1.
Case 2 was a 54-year-old Turkish woman who presented with a 3-cm nodule on her right thyroid lobe. She had
undergone surgery for a right lung mass four years previously. After a right pneumonectomy, thymectomy and
lymph node dissection, a typical carcinoid tumor was diagnosed. Under ultrasonographic guidance, fine needle
aspiration biopsy of her right thyroid pole nodule was performed and the biopsy was compatible with a
neuroendocrine tumor metastasis. She was treated with a bilateral total thyroidectomy. Histopathological
examination indicated three nodular lesions, 5 cm and 0.4 cm in diameter in her right lobe and 0.1 cm in diameter
in her left lobe. The tumors were consistent with a neuroendocrine phenotype, showing strong immunoreactivity
to chromogranin A and synaptophysin.
Conclusion: Thyroid nodules detected during follow-up of neuroendocrine tumor patients should be thoroughly
investigated. A fine needle aspiration biopsy of the thyroid confirms the diagnosis in most cases and leads to
appropriate management of those patients and may prevent unnecessary treatment approaches.
Introduction
Neuroendocrine tumors may cause paraneoplastic syn-
dromes by secreting endogenous hormone-active sub-
stances. The resulting symptoms may mask the primary
tumor and cause a delay in diagnosis, which eventually
leads to metastatic disease. During the disease course, a
thyroid metastasis mimicking medullary carcinoma may
rarely develop, making the diagnosis even more compli-
cated. Two cases of thyroid metastasis from neuroendo-
crine tumors are described in this paper, with a




A 17-year-old Turkish female patient was referred from
our endocrinology department for a thyroidectomy to
treat a neuroendocrine tumor metastasis. Our patient
had presented to a university hospital 30 months pre-
viously, with dysmenorrhea, hirsutism and facial swel-
ling. Her symptoms were investigated and she was
suspected of having ectopic Cushing’s syndrome. At that
time, magnetic resonance imaging (MRI) of her sella
turcica was performed, with normal findings. Her 24-
hour urinary free cortisol level was 159 μg/day, and her
basal adrenocorticotropic hormone (ACTH) concentra-
tion was 80 pg/mL. She was referred to our endocrinol-
ogy department one month later and the investigations
were repeated. Biochemical findings indicated ACTH-
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dependent Cushing’s syndrome. Her ACTH and 24-hour
urinary free cortisol concentrations were 106 pg/mL and
240 μg/day respectively. A high-dose (8 mg) dexametha-
sone suppression test revealed non-suppressible cortisol
concentrations. Cushing’s syndrome due to ectopic
ACTH secretion was suspected. An ultrasonagraph
(USG) of her thyroid revealed normal findings. There
was no abnormality on thoracic computed tomography
(CT) and on adrenal MRI findings.
Her serum calcitonin levels were within the normal
range. Her 24-hour urine metanephrines and 5-hydro-
xyindoleacetic acid (5-HIAA) concentrations were
within their respective normal ranges. Sampling of her
inferior petrosal sinus was performed and revealed a
central-to-periphery ACTH ratio of below 1.8, which
indicates ectopic ACTH secretion. Octreotide scintigra-
phy was performed, which revealed scarce activity in her
upper mediastinum.
Close follow-up was planned for this patient; however,
she did not attend her appointments. Two years later, in
August 2009, she presented with worsening of her initial
symptoms. MRI of her abdomen and sellar was per-
formed, demonstrating normal findings. A USG of her
thyroid detected a 1 cm nodule at the right lower pole,
and fine needle aspiration (FNA) revealed non-diagnos-
tic material. Her ACTH concentrations were high (153
pg/mL) and her 24-hour urinary cortisol concentration
was 2454 μg/day. Her thyroid function test results were
within normal limits. A thoracic CT demonstrated med-
iastinal lymphadenopathies (LAPs). She was referred to
our thoracic surgery department and a mediastinoscopy
was performed.
Histopathological evaluation revealed a metastatic
neuroendocrine tumor on her lymph nodes. Positron
emission tomography-CT revealed hypermetabolic LAPs
in her right supraclavicular, left prevascular mediastinal,
right upper paratracheal and anterior mediastinal
regions and disseminated bony metastases. The primary
tumor site was not diagnosed. Her urinary 5-HIAA was
within normal limits (2.88 mg/day; normal range: 2.0
mg/day to 9.0 mg/day). Bone scintigraphy revealed
pathological activities at the superior portion of her
medial left scapular border; her thoracic vertebrae T7,
T10 and T11; her right sacroiliac joint; her inferior right
acetabular region; and the posterior portion of her right
eighth rib, indicating metastases.
Our patient was started on 30 mg of octreotide long-
acting release (LAR) every 28 days with the aim of con-
trolling her ectopic ACTH secretion and tumor progres-
sion. A reoperation was planned to remove the
mediastinal masses. Excision of the mediastinal mass,
mediastinal LAP and right supraclavicular LAP was per-
formed via upper sternotomy. Histopathological and
immunohistochemical analyses revealed a metastatic
atypical carcinoid tumor with positive ACTH immunos-
taining and a 10% Ki-67 labeling index. After the opera-
tion, an amelioration of the signs and symptoms of
Cushing’s syndrome was observed and our patient’s
basal ACTH concentration decreased to 88.6 pg/mL.
She remained on the octreotide-LAR treatment.
One month after surgery, a repeated thyroid USG
showed that the previously detected thyroid nodule had
increased in size (15 mm at its maximum diameter).
Under USG guidance, FNA of her right thyroid pole
nodule was performed, and the aspirate was compatible
with a neuroendocrine tumor metastasis. Our patient
was treated with a bilateral total thyroidectomy. Gross
examination of the thyroidectomy specimen demon-
strated a solitary nodule 1.8 cm × 1.4 cm × 0.8 cm in dia-
meter. Histopathology results were consistent with a
neuroendocrine tumor. Neoplastic cells showed strong
immunoreactivity to chromogranin A and synaptophysin,
but the immunohistochemical profile was inconsistent
with medullary thyroid carcinoma in that the tumor was
negative for calcitonin, carcinoembryonic antigen (CEA),
and thyroid transcription factor-1 (TTF-1) (Figure 1).
Our patient is still being followed up at our institu-
tion. Her metastatic lesions are stable on octreotide
LAR 30 mg/day. However, progressive deterioration in
signs and symptoms of Cushing’s syndrome (that is, glu-
cose intolerance, hypertension, myopathy and osteo-
porosis) led us to determine that a bilateral
adrenalectomy should be performed on this patient.
Figure 1 Case 1: singly distributed neoplastic cells showing
salt-and-pepper chromatin consistent with a neuroendocrine
neoplasm (×60 Papanicolaou stain).
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Case 2
A 54-year-old Turkish woman presented with a 3 cm
nodule on her right thyroid lobe. She had undergone
surgery for a right lung mass in February 2007. After a
right pneumonectomy, thymectomy and lymph node
dissection, a typical carcinoid tumor was diagnosed and
she was maintained on regular follow-up. Her serum
calcitonin was within the normal range. Ectopic hor-
mone syndrome was not identified. Under USG gui-
dance, FNA of her right thyroid pole nodule was
performed, and the biopsy was compatible with a neu-
roendocrine tumor metastasis. She was treated with a
bilateral total thyroidectomy. A histopathological exami-
nation indicated three nodular lesions, 5 cm and 0.4 cm
in diameter in the right lobe and 0.1 cm in diameter in
the left lobe. The tumors were consistent with a neu-
roendocrine phenotype; showing strong immunoreactiv-
ity to chromogranin A and synaptophysin, but the
immunohistochemical profile was inconsistent with
medullary thyroid carcinoma in that the tumor was
negative for calcitonin, CEA and TTF-1 (Figure 2).
Discussion
Although the thyroid gland has an affluent blood supply,
solid tumor metastases to the thyroid are seldom
reported during follow-up. Lin et al. [1] reported that
14 of 1,013 patients (1.4%) with thyroid cancer verified
on histology had metastatic tumors; adenocarcinoma
and squamous cell carcinoma were the most frequently
detected histological types [1]. Results of autopsy series
have indicated that metastases to the thyroid gland have
been found in up to 24% of patients who have died of
cancer [1,2]. Therefore, in most cases, thyroid metastasis
remains clinically silent.
Metastases to the thyroid should be a sign of more
widespread disease. Lin et al. [1] reported that most of
their patients with thyroid metastases died within nine
months of diagnosis. However, in some slowly growing
tumors, a relatively longer survival is still possible, as
observed in our first patient. Aggressive tumors lead to
painful thyroid nodules with rapid growth and local
compression symptoms. Thyrotoxicosis due to destruc-
tive thyroiditis has also been described [3,4]. In both of
our patients, thyroid function test results were within
normal limits and local symptoms were not evident.
The slow growth of well-differentiated neuroendocrine
tumors could be responsible for the absence of thyroid
destruction and local symptoms. Thyroid metastases
were detected two and three years after the diagnosis of
neuroendocrine tumors in our first and second patients,
respectively. Lam and Lo [5] reported that the mean
latency period between diagnosis of primary tumors and
thyroid metastasis was nine months in their series.
In most cases, breast, lung, stomach and renal cell car-
cinomas are responsible for metastatic thyroid lesions
[1,2,5]. To the best of our knowledge, seven thyroid
metastases of neuroendocrine tumors have previously
been reported [6-12]. Matias-Guiu et al. [13] reported
an additional six patients in whom the diagnosis was
confirmed by their immunohistochemical profile and
morphologic findings of tumor tissue. When the diagno-
sis of a primary tumor is not apparent, thyroid metas-
tases of neuroendocrine carcinoma may lead to
diagnostic confusion. Metastatic thyroid lesions from
neuroendocrine tumors may mimic medullary thyroid
carcinoma on cytology or on histopathology [7,10,13].
Immunohistochemical markers such as chromogranin A,
neuron-specific enolase and synaptophysin are report-
edly positive for both medullary thyroid and metastatic
neuroendocrine carcinoma [11,12]. Calcitonin and CEA
immunohistochemistry should be negative in metastatic
neuroendocrine tumors, but positive staining is observed
in medullary thyroid cancer [7,11,12]. Calcitonin immu-
nostaining may even be positive in neuroendocrine
tumors [12,14]. In particular, the small cell variant of
medullary thyroid carcinoma has been reported to
resemble small cell pulmonary neuroendocrine carci-
noma [15]. In our patients, the previous non-thyroidal
neuroendocrine carcinoma diagnosis and normal serum
calcitonin concentrations were adequate for accurate
diagnosis in addition to the histopathological and immu-
nohistochemical findings of thyroid metastases.
Neuroendocrine tumors may present with paraneo-
plastic syndromes, which may mask the primary lesion.
Our first patient had ectopic ACTH syndrome, which
was responsible for her comorbidities. Bronchial carci-
noid tumors are reportedly the most frequent cause of
ectopic ACTH secretion [16]. Despite a stable metastatic
Figure 2 Case 2: plasmacytoid monotonous epithelial cells
forming loose groups compatible with a neuroendocrine
neoplasm (×60; May-Grünwald-Giemsa stain).
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disease, our patient had progressively worsening signs
and symptoms of Cushing’s disease. Therefore, a bilat-
eral adrenalectomy was considered. Somatostatin ana-
logs have been used for the treatment of ectopic ACTH
secretion with varied success rates [17,18]. During long-
term treatment, antiproliferative and antisecretory
effects of octreotide treatment for endocrine tumors
may dissociate, leading to sustained antiproliferative but
lessened antisecretory effects [19]. In our first patient,
we believe that the antisecretory effects of octreotide
LAR have diminished but that the antiproliferative
effects are still obvious because no considerable increase
in the size of her metastatic lesions has been observed.
Different mechanisms have been proposed to explain
the resistance to the antisecretory effects of octreotide
during treatment, such as different expression patterns
of somatostatin receptor subtypes [19,20]. On the other
hand, an increase in the mass of secondary deposits
under the detection limit of radiologic imaging techni-
ques could be responsible for the exacerbation of Cush-
ing’s syndrome characteristics in our first patient. An
increase in the dose of somatostatin analogs may over-
come this resistance. Alternatively, medical or chemical
adrenalectomy should be considered.
Conclusion
It is important to consider the possibility of metastasis
in patients with thyroid nodules and a history of a pri-
mary malignant tumor. Thyroid nodules detected during
follow-up of patients with neuroendocrine tumors
should be thoroughly investigated. Thyroid fine-needle
aspiration biopsy confirms the diagnosis in most cases,
leads to appropriate management of these patients, and
may prevent unnecessary treatment approaches.
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